Please assess the completion status of the following clinical trial:

Trial Title: Oxaliplatin and Prednisolone (Ox-P) for Patients With Relapsed or Refractory Marginal Zone B-cell Lymphoma(MZL)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed marginal zone B-cell lymphomas~* Failure to achieve a clinical benefit (≥SD) with the initial treatment, or recurrent disease~* Performance status (ECOG) ≤2~* Age ≥ 20~* At least one or more bi-dimensionally measurable lesion(s) defined as; ≥2 cm by conventional CT or ≥ 1 cm by spiral CT or skin lesion (photographs should be taken) or measurable lesion by physical examination~* Adequate kidney functions defined as; Cr \< 2.0 mg% or Ccr \> 60 ml/min~* Adequate liver functions defined as; Transaminases \< 3 X upper normal values; Bilirubin \< 2 mg%~* Adequate bone marrow functions defined as; ANC \> 1500/㎕, platelet \> 75000/㎕~* Ann Arbor stage III or IV~* Ann Arbor stage I or II, which is not adequate for RT or surgical approach (e.g. multiple lung lesions, multiple colon involvement, remote abdominal LN with stomach involvement)~* Written informed consent approved by Institutional review board or Ethic committee~Exclusion Criteria:~* Any other malignancies within the past 5 years except skin basal cell ca or CIS of cervix~* Serious co-morbid diseases~* Pregnancy or breast feeding~* Previous history of drug allergy to one of the drugs in the study regimen~* During this study duration, patients who take other clinical trial medication, chemotherapy, hormonal therapy, or immunotherapy

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- OXP (Type: EXPERIMENTAL): Oxaliplatin 130mg/m2 + 5DW 500ml MIV over 2HR D1 Prednisolone 100mg/Day D1-D5 Every 3 weeks Maximum 6 cycles of treatment will be given for this study. Subjects will be treated for at least 1 cycle and to a maximum of 6 cycles unless there is documented disease progression, unacceptable adverse events or withdrawal of consent.

Based on this trial design, predict the completion outcome and termination type (if applicable).